

# BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY

Fifth Edition

Volume I: Principles and Practice

Edited by

Manfred E. Wolff

ImmunoPharmaceuticals, Inc.  
San Diego, California



A WILEY-INTERSCIENCE PUBLICATION

JOHN WILEY & SONS, Inc., New York • Chichester • Brisbane • Toronto • Singapore

# BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY

Fifth Edition

Volume I: Principles and Practice

Edited by

Manfred E. Wolff

ImmunoPharmaceutics, Inc.  
San Diego, California



A WILEY-INTERSCIENCE PUBLICATION

JOHN WILEY & SONS, Inc., New York • Chichester • Brisbane • Toronto • Singapore

*Notice Concerning Trademark or Patent Rights.*

The listing or discussion in this book of any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as a grant of, or authority to exercise, or an infringement of, any right or privilege protected by such patent or trademark.

This text is printed on acid-free paper.

Copyright © 1995 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, 605 Third Avenue, New York, NY 10158-0012.

*Library of Congress Cataloging in Publication Data:*

Burger, Alfred, 1905–

[Medicinal chemistry]

Burger's medicinal chemistry and drug discovery. -- 5th ed. /  
edited by Manfred E. Wolff.

p. cm.

"A Wiley-Interscience publication."

Contents: v. 1. Principles and practice

Includes bibliographical references and index.

ISBN 0-471-57556-9

1. Pharmaceutical chemistry. I. Wolff, Manfred E. II. Title.

III. Title: Medicinal chemistry and drug discovery.

RS403.B8 1994

615'.19--dc20

94-12687

Printed in the United States of America

10 9 8 7 6 5 4 3

# Burger's Medicinal Chemistry and Drug Discovery



Dr. Alfred Burger

# Preface

*Did we know the mechanical affectations of the particles of rhubarb, opium, and a man, as a watchmaker does those of a watch, whereby it performs its operations, and of a file which by rubbing on them will alter the figure of any of the wheels; we should be able to tell beforehand that rhubarb will purge, hemlock kill and opium make a man sleep.*

*John Locke, Essay on the Human Understanding, 1690*

Drug discovery has its roots in the beginnings of mankind. Even our phylogenetic cousins, the chimpanzees, have been observed to chew certain leaves to alleviate gastrointestinal distress. Likewise, in the evolution of the early hunter-gatherer communities it was only a short step from gathering vegetation to be eaten to assuage the pangs of hunger, to gathering material to be ingested to diminish the pain and discomfort of illness or injury. Thus, drug discovery has been important in every society, whether in the primitive tribes of North America or Africa, in the advanced classical Egyptian, Greek, and Roman civilizations, or in the more recent cultures of Europe, Asia, India, and elsewhere.

Today we are in the midst of an explosive expansion in the organized, purposeful discovery of drugs—an expansion that has occurred in the fifteen years that have elapsed since the previous edition of this series. Three forces are responsible for this growth. The first is the dawn of the golden age of biology, the stunning progress that has been made in structural biology and

molecular biology, and its impact on the drug discovery process. The second is the information processing and transfer revolution that has made it possible to utilize all of the older and contemporary knowledge effectively in our new information society. And the third is the dramatic increase in the size of the world pharmaceutical market.

Science has never been confined by geographic boundaries. But in the past fifteen years, globalization, not only of technology itself, but of an appetite for the fruits of technology, has proceeded at an ever faster rate—the revolution of rising expectations. Nowhere is this more evident than in the desire of individuals everywhere to have the benefit of the best drugs available anywhere. The result has been to triple the world pharmaceutical market in ten years to \$145 billion in 1989, compared to about \$50 billion in 1979. Only six countries, the United States, Japan, Germany, Italy, France and the United Kingdom, are responsible for \$113 billion (78%) of this sum. These countries represent only a fraction of the world population, and it is obvious that even greater growth is probable. In the past, a substantial part of such increases has resulted from simple price elevation. But the drive for cost containment in healthcare will ensure that most future growth will come from innovative new products and from market expansion.

The widening of the world pharmaceutical market has resulted in two collateral expansions. The first is in drug discovery research and development, both in absolute magnitude as well as in proportion to

product sales. For example, global R&D spending of PMA member companies as a percentage of sales changed from about 9% in 1980 to more than 15% in 1990. In addition, the absolute magnitude of U.S. R&D spending by PMA companies rose from about \$2 billion in 1980 to about \$7 billion in 1989. These increases have resulted in a dramatic expansion in the growth rate of pharmaceutical R&D spending in the U.S., as well as in the EC and Japan. Adjusted for inflation, the real growth in U.S. pharmaceutical R&D spending during 1975–1980 was only 3.5% per year. By contrast, during 1980–1990, the period since the publication of the preceding edition of this series, it was nearly 11% per year.

A second collateral expansion driven by the rapidly widening world pharmaceutical market has been in the number of pharmaceutical companies in operation, and being newly formed. It is a remarkable fact that there are hundreds of these, principally in the U.S., but also in the EC and elsewhere.

That these companies are attractive to the sources of financial capital necessary for their existence and operation is due to their potential for new drug discovery, and to the expectation of substantial profits from the sale of these new drugs. For this reason, such companies collectively employ thousands of scientists in the drug discovery area—scientists in laboratories and research programs that did not exist only a few years ago.

Not only has the scope and magnitude of drug discovery efforts expanded greatly, but the complexity, management challenges, and human resource requirements of the task have been correspondingly magnified. The new technologies, molecular biology, computational chemistry, the new analytical methods, and others, have combined to produce a more intellectually satisfying and effective, albeit more complex process. At the same time, increasingly stringent regulatory requirements with

respect to novelty, efficacy and safety have made the development phase following drug discovery a more difficult undertaking. It is important that these later hurdles be fully appreciated by those workers active in the earlier aspects of drug discovery.

During the past decade, these drastically changed circumstances surrounding drug discovery created a much enlarged group of individuals involved in the search for new drugs. That group comprises not only academic and industrial scientists in the disciplines of biology, biotechnology, chemistry, physics, pharmaceuticals and mathematics, but also clinicians, regulatory experts, financial analysts, lawyers, managers, and of course students and postdoctorals in all of these areas.

For success in the search for new drugs, full and complete communication is necessary between these many different individuals and disciplines. Drug discovery is above all an interdisciplinary effort—a team effort. As such, a contract lawyer may need to be aware of issues involved in the receptor specificity of ligands. A chemist may need to be conversant with aspects of patent law. A financial analyst may need to understand the potential of 3D database searches. A senior manager may need to appreciate the timing requirements of clinical trials. In this volume we attempt to inform such individuals in all of these areas.

Because numerous new factors must be considered in drug discovery, and a variety of individuals with widely divergent backgrounds now take part in it, the prophetic words of John Locke, which appeared in past editions and are given again at the beginning of this preface, address only a part of the task. Indeed, there are cases now where an x-ray crystallographic image of an enzyme inhibitor complex satisfies Locke's requirement for knowledge of the "mechanical affectations" of the drug and the patient. But we know now that this is not enough—that we must also have knowl-

---

**One Hundred Newer Pharmaceutical Companies**


---

Advanced Tissue Sciences	Creative Biomolecules	Magainin
Affinity Biotechnology	Curative Technologies	Matrix
Affymax	Cytel Corp.	Medarex
Agouron	Cytogen	MedImmune
Alkermes	Cyto Therapeutics	NeoRx
Alpha-Beta	DNX Corporation	Oculon
Alteon	Emisphere	Oncogene Science
Amgen	Enzon	Ogranogenesis
Amylin	Genelabs Technologies	Osteotech
Anèrgen	Genentech	PerSeptive Biosystems
Applied Immune Sciences	Genetic Therapy	Procyte
Arris	Genetics Institute	Protein Design Labs
Athena Neurosciences	Gensia	Regeneron
Autoimmune	Genta	Repligen
Biocryst	Genzyme	Ribi ImmunoChem
Biogen	Gilead Sciences	Scios Nova
Biomatrix	Glycomed	Sergen
Biomira	ICOS	Shaman Pharmaceuticals
BioSurface	IDEC	Somatogen
Bio-Technology General	IGI, Inc.	Sphinx
British Bio-Technology	ImClone	Synergen
Cambridge Biotechnology	ImmuLogic	SyStemix
Cambridge Neurosciences	Immune Response	T Cell Sciences
Cellcor	Immunex	Telios
Cell Genesys	ImmunoGen	Texas Biotechnology
CellPro	Immunomedics	TSI Corp.
Celtrix	ImmunoPharmaceutics	Univax Biologics
Centocor	Isis Pharmaceuticals	US Bioscience
Cephalon	LifeCell	Vertex
Chiron	Ligand	Vestar
CoCensys	Liposome Company	Xenova
COR Therapeutics	Liposome Technology	Xoma
Cortech		Zynaxis
Corvas		

---

edge of drug metabolism, toxicity, a means to demonstrate decisive clinical efficacy, and a host of other matters, in order to be able to discover new drugs. An attempt has been made to provide an overview of all of these areas in this volume, entitled "Principles and Practices".

In preparing this new edition of these volumes founded through the vision of Alfred Burger, an effort has been made to incorporate the new developments into the discussion in every place where it has been possible. In this first volume, particular

attention has been paid to product development questions which should be considered early in the discovery phase. We begin with a consideration of the conceptual background of medicinal chemistry by Alfred Burger, and continue with the management of drug discovery and the accessing and protection of information and intellectual property. In the second section, product development issues that are important to the discovery process are reviewed—questions of ADME, toxicity and drug allergy, and clinical trial issues. In part III, the



extensive advances that have been made in the structural biology of drug action are considered. And in the final section, the technologies for drug discovery, largely developed in the years since the preceding edition, are examined.

As indicated above, we hope that this volume will prove useful to all practitioners of drug discovery as well as graduate students and postdoctorals with these interests. We hope also that it will inform those interested in other types of biological actions of chemicals and biotechnology products, such as the environmental toxicity of herbicides and pesticides, or the effects of food additives. And, finally, we hope that it will serve as a suitable introduction and companion volume for the specialized chapters in the other volumes of this series.

I wish to express my sincere gratitude to the many persons who have made this new edition possible. Most of all, I thank the dedicated, knowledgeable authors, who have given so generously of their time in

order to pass their expertise on to others, and many of whom have shared with me the benefit of their own views on the general topic of drug discovery. They and others have helped me enormously in defining the scope of this first volume, but ultimately the responsibility for any deficiencies in this regard is mine alone. I am grateful to the editorial staff of John Wiley & Sons for their longstanding interest in this series. I wish especially to express my sincere appreciation to Lisa Trout, who organized and kept track of the voluminous correspondence resulting from so many interactions, and who tactfully managed finally to get all the manuscripts out of the hands of the authors. And finally I thank my wife, Gloria, for her enduring support and sustenance for all of my efforts.

MANFRED E. WOLFF

*San Diego, California*  
*January, 1995*

# Burger's Medicinal Chemistry and Drug Discovery

# Contents

## Part I The Drug Discovery Process, 1

1. THE CONCEPTUAL BACKGROUND AND DEVELOPMENT OF MEDICINAL CHEMISTRY, 3

Alfred Burger  
*Charlottesville, Virginia, USA*

2. THE MANAGEMENT OF DRUG DISCOVERY, 9

Ralph E. Christofferson and J. Joseph Marr  
*Ribozyme Pharmaceuticals, Inc.  
Boulder, Colorado, USA*

3. INTELLECTUAL PROPERTY IN DRUG DISCOVERY AND BIOTECHNOLOGY, 37

Richard A. Kaba, David A. Crossman and Julius Tabin  
*Fitch, Even, Tabin Flannery  
Chicago, Illinois, USA*

4. INFORMATION SCIENCE IN DRUG DISCOVERY, 103

Y. Lin Chang and Linda M. Klug  
*Marion Merrell Dow, Inc.  
Kansas City, Missouri, USA*

## Part II Product Development Issues, 111

5. DRUG ABSORPTION, DISTRIBUTION AND ELIMINATION, 113

Leslie Z. Benet and Beatrice Y. T. Perotti  
*Department of Pharmacy  
University of California  
San Francisco, California, USA*

6. DRUG METABOLISM, 129

Bernard Testa  
*Institut de Chimie Thérapeutique  
Ecole de Pharmacie  
Université de Lausanne  
Lausanne, Switzerland*

7. DRUG ALLERGY, 181

Charles W. Parker  
*Department of Medicine  
Washington University School of Medicine  
St. Louis, Missouri, USA*

8. THE APPLICATION OF STRUCTURAL CONCEPTS TO THE PREDICTION OF THE CARCINOGENICITY OF THERAPEUTIC AGENTS, 223

Herbert S. Rosenkrantz  
*Department of Environmental and Occupational Health*

*Graduate School of Public Health  
University of Pittsburgh  
Pittsburgh, Pennsylvania, USA*

*Gilles Klopman  
Department of Chemistry  
Case Western Reserve University  
Cleveland, Ohio, USA*

9. FROM DISCOVERY TO MARKET:  
THE DEVELOPMENT OF  
PHARMACEUTICALS, 251

*Jan I. Drayer and James P. Burns  
G.H. Besselaar Associates  
Princeton, New Jersey, USA*

Part III Structural Medicinal Chemistry, 301

10. THREE DIMENSIONAL  
STRUCTURE-AIDED DRUG  
DESIGN, 303

*B. Veerapandian  
La Jolla Cancer Research  
Foundation  
La Jolla, California, USA*

12. DRUG-TARGET BINDING  
FORCES, 399

*Peter A. Kollman  
Department of Pharmaceutical  
Chemistry  
School of Pharmacy  
University of California  
San Francisco, California, USA*

11. DRUG RECEPTORS, 349

*Michael Williams, Darlene C. Deecher  
and James P. Sullivan  
Pharmaceutical Products Division  
Abbott Laboratories  
Abbott Park, Illinois, USA*

Part IV Drug Discovery Technologies, 413

13. CHEMICAL INFORMATION  
COMPUTING SYSTEMS IN DRUG  
DISCOVERY, 415

*Stephen W. Dietrich  
Molecular Computing Systems, Inc.  
Bothell, Washington, USA*

15. MOLECULAR MODELING IN  
DRUG DESIGN, 573

*Garland R. Marshall  
Center for Molecular Design  
Washington University  
St. Louis, Missouri, USA*

14. THE QUANTITATIVE ANALYSIS  
OF STRUCTURE-ACTIVITY  
RELATIONSHIPS, 497

*Dr. Hugo Kubinyi  
Wirkstoffdesign  
BASF Aktiengesellschaft  
Ludwigshafen, Germany*

16. APPLICATION OF RECOMBI-  
NANT DNA TECHNOLOGY IN  
MEDICINAL CHEMISTRY AND  
DRUG DISCOVERY, 661

*Michael C. Venuti  
Parnassus Pharmaceuticals, Inc.  
Alameda, California, USA*

17. MASS LIGAND SCREENING AS A TOOL FOR DRUG AND DEVELOPMENT DISCOVERY, 697  
Paul M. Sweetnam  
*Pfizer Central Research*  
*Groton, Connecticut, USA*  
  
Christopher H. Price  
*Medical Innovation Partners*  
*Minneapolis, Minnesota, USA*  
  
John W. Ferkany  
*Nova Screen and Oceanix Biosciences Corp.*  
*Baltimore, Maryland, USA*
- ✓ 18. APPROACHES TO THE RATIONAL DESIGN OF ENZYME INHIBITORS, 733  
Angelika Muscate and George L. Kenyon  
*School of Pharmacy*  
*University of California*  
*San Francisco, California, USA*
19. ANALOG DESIGN, 783  
Joseph G. Cannon  
*College of Pharmacy*  
*University of Iowa*  
*Iowa City, Iowa, USA*
- ✓ 20. PEPTIDOMIMETICS FOR DRUG DESIGN, 803  
Murray Goodman  
*Department of Chemistry*  
*University of California, San Diego*  
*San Diego, California, USA*  
  
Seonggu Ro  
*Research and Development Park of LUCKY Ltd.*  
*Biotechnology Science Town*  
*Daejeon, Korea*
21. OLIGONUCLEOTIDE THERAPEUTICS, 863  
Stanley T. Crooke  
*Isis Pharmaceuticals*  
*Carlsbad, California, USA*
22. CARBOHYDRATE-BASED THERAPEUTICS, 901  
John H. Musser, Péter Fügedi and Mark Brian Anderson  
*Glycomed Inc.*  
*Alameda, California, USA*
23. METABOLIC CONSIDERATIONS IN PRODRUG DESIGN, 949  
L. P. Balant and E. Doelker  
*Institutions Universitaires de Psychiatrie de Genève*  
*Unité de Recherche Clinique*  
*Genève, Switzerland*
- ✓ 24. NATURAL PRODUCTS AS LEADS FOR NEW PHARMACEUTICALS, 983  
Dr. A. D. Buss  
*Department of Natural Products Discovery*  
*Glaxo Research and Development Ltd.*  
*Middlesex, England*  
  
R. D. Waigh  
*Department of Pharmaceutical Sciences*  
*Royal College*  
*University of Strathclyde*  
*Glasgow, Scotland*
- INDEX, 1035

# PART I THE DRUG DISCOVERY PROCESS



## CHAPTER ONE

# The Conceptual Background and Development of Medicinal Chemistry

ALFRED BURGER

### CONTENTS

- 1 Introduction, 3
- 2 Natural Products, 3
- 3 Molecular Modification, 4
- 4 "Lead" Compounds, 5
- 5 Receptors, 6

### 1 INTRODUCTION

Medicinal chemistry had its beginning when chemists, pharmacists, and physicians isolated and purified active principles of plant and animal tissues and later from micro-organisms and their fermentation products. Some of these chemicals had been associated with therapeutic properties in often ill-defined disease conditions. During the latter decades of the 20th century, the traditional dividing lines between biological, chemical, and physical sciences were erased, and new borderline investigations such as molecular biology, molecular

pharmacology, biomedicine, and others began to capture the interest of medicinal scientists. Medicinal chemistry which had leaned on the classical fields of chemistry, especially organic chemistry, biology and some areas of physics extended new roots into these emerging topics. Problems in hitherto unapproachable chemical studies with therapeutic implications became accessible and revised the choice of researches to the benefit of all the scientific doctrines involved.

### 2 NATURAL PRODUCTS

The elucidation of the structure and function of natural products, especially those with a history of biological properties, has been an important incentive for organic

---

*Burger's Medicinal Chemistry and Drug Discovery*,  
Fifth Edition, Volume 1: Principles and Practice,  
Edited by Manfred E. Wolff.  
ISBN 0-471-57556-9 © 1995 John Wiley & Sons, Inc.



chemistry. Learning how Nature handles the synthesis and degradation of such substances is a deeply fulfilling and exciting goal of organic and medicinal chemists and of biochemists. One can never stop marveling at the ingenuity of Nature which creates unexpected and often amazingly novel structures by biosynthetic and degradative reactions. The apparent purpose of these metabolic chemical reactions is to rid the parent organism of unwanted or toxic substances. In some cases, toxic metabolites may be useful in protecting the organism against predators or environmental hazards. There is no support for the belief that natural metabolites of plants and animals are produced for therapeutic uses by humans, even though humans have learned to harvest and process some of them for the maintenance of their homeostasis.

Over the last 200 years, natural products have been screened by experimental biologists who devised increasingly meaningful animal models of clinical pathologies. More recently, *in vitro* inhibition data of enzyme systems have simplified some of these tests and deepened our understanding of the mode of action of drugs.

A limited number of natural products can serve directly as therapeutic agents although lack of specificity frequently limits their application in human and veterinary medicine and in analogous pesticidal and other uses in agriculture. However, their never-ending variety and novelty serves as a source of prototype compounds for molecular modification. By dissecting the structure of a natural product chemically, one arrives at its therapeutically significant molecular sections, the pharmacophores. The portions that can be deleted are of no interest as components of drug action; they are regarded as the result of the biosynthetic efforts of the parent organism to construct materials for its own metabolic or defensive purposes.

Some structurally relatively uncomplicated biocatalysts such as several hormones

and vitamins were originally regarded as uniquely designed for their biological mission and chemists were reluctant to interfere. It is now hard to imagine what impact their first molecular modifications had on contemporary thinking (1-5).

### 3 MOLECULAR MODIFICATION

When synthetic organic chemicals overtook the number of natural products, synthetic compounds offered an opportunity to medicinal screening. Some kind of selection of candidate compounds had to be made because dipping blindly into the supply of millions of synthetic compounds would have put the lottery to shame. Therefore, synthetic derivatives and structural analogues of biologically interesting substances were tested first for activities associated with the "lead" compound. Such programs included the branching, lengthening or shortening of chain structures, the variation of the kinds and positions of substituents, the replacement of rings by similar cyclic structures, and other empirical molecular modifications within the framework of reasonably close analogy. Functional groups were replaced by similar reactive radicals and occasionally an unorthodox change was tried. Many of the alterations were dictated by synthetic accessibility in a given structural series, without regard to biochemical reasoning.

As could be expected, close structural analogues of a biologically active material had a better chance of being similarly active than more remote analogues. The batting average among random variations was and still is low, ranging from 1:5,000 to even 1:10,000 for elaborating a drug that can survive screening and preclinical evaluation. Such systematic molecular modifications are not profitable; nevertheless, they remain the principal approach to new drug structures. It is a monument to human patience that so many valuable drugs have been developed by this method.